Ignite Creation Date:
2024-05-05 @ 6:30 PM
Last Modification Date:
2024-10-26 @ 9:34 AM
Study NCT ID:
NCT00491322
Status:
COMPLETED
Last Update Posted:
2018-05-02
First Post:
2007-06-22
Brief Title:
Vitamin D Deficiency Insulin Resistance and FGF-23
Sponsor:
Massachusetts General Hospital
Organization:
Massachusetts General Hospital
Study Overview
Official Title:
Impact of Vitamin D Deficiency on Insulin Resistance and the Regulation of FGF-23
Status:
COMPLETED
Status Verified Date:
2018-04
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this project is to determine if treating vitamin D deficiency decreases insulin resistance and improves insulin secretion in healthy volunteers Additionally this project will investigate if treating vitamin D deficiency affects a new phosphate-regulating hormone called FGF-23
Detailed Description:
Vitamin D deficiency or hypovitaminosis D defined as serum 25 hydroxyvitamin D or 20 ngmL is prevalent in several populations in the United States specifically minorities and the elderly Causes of vitamin D deficiency include lack of exposure to sunlight malnutrition and drugs that alter vitamin D metabolism and absorption
Vitamin D is an essential factor for many organ systems Data suggest that vitamin D is required for normal insulin secretion by the pancreas Specifically animal studies demonstrate that treatment of vitamin D deficiency improves insulin secretion In humans there is less consensus about the impact of vitamin D deficiency on insulin resistance In one study of middle-aged patients with Type 2 diabetes mellitus no association was seen between serum 25 hydroxyvitamin D levels and a measure of insulin resistance However in a larger study of younger glucose tolerant subjects serum 25 hydroxyvitamin D levels were associated with both insulin secretion and insulin resistance These data suggest that treatment of vitamin D deficiency may delay or prevent the development of insulin resistance and thus diabetes mellitus type 2 Repletion of this common vitamin deficiency could therefore have major public health implications for the prevention of diabetes mellitus
Fibroblast growth factor 23 FGF-23 is a newly discovered phosphaturic hormone that is regulated by both dietary and serum phosphate Hormonal regulation of FGF-23 however is largely unknown Recent data suggest that vitamin D plays an important role in the regulation of FGF-23 Some groups have shown that inactivation of the vitamin D receptor gene decreases serum FGF-23 levels in mice administration of 125 dihydroxyvitamin D stimulates the transcription of the FGF-23 gene in vitro Little is known however about the regulation of FGF-23 by vitamin D in humans
Phosphate is critical for bone mineralization muscle function signal transduction and the creation and utilization of energy Vitamin D deficiency can result in phosphate malabsorption osteomalacia and increased risk of fractures Enhanced understanding of the regulation of this new phosphate-regulating hormone FGF-23 will advance the field of phosphate metabolism
Vitamin D is an essential factor for many organ systems Data suggest that vitamin D is required for normal insulin secretion by the pancreas Specifically animal studies demonstrate that treatment of vitamin D deficiency improves insulin secretion In humans there is less consensus about the impact of vitamin D deficiency on insulin resistance In one study of middle-aged patients with Type 2 diabetes mellitus no association was seen between serum 25 hydroxyvitamin D levels and a measure of insulin resistance However in a larger study of younger glucose tolerant subjects serum 25 hydroxyvitamin D levels were associated with both insulin secretion and insulin resistance These data suggest that treatment of vitamin D deficiency may delay or prevent the development of insulin resistance and thus diabetes mellitus type 2 Repletion of this common vitamin deficiency could therefore have major public health implications for the prevention of diabetes mellitus
Fibroblast growth factor 23 FGF-23 is a newly discovered phosphaturic hormone that is regulated by both dietary and serum phosphate Hormonal regulation of FGF-23 however is largely unknown Recent data suggest that vitamin D plays an important role in the regulation of FGF-23 Some groups have shown that inactivation of the vitamin D receptor gene decreases serum FGF-23 levels in mice administration of 125 dihydroxyvitamin D stimulates the transcription of the FGF-23 gene in vitro Little is known however about the regulation of FGF-23 by vitamin D in humans
Phosphate is critical for bone mineralization muscle function signal transduction and the creation and utilization of energy Vitamin D deficiency can result in phosphate malabsorption osteomalacia and increased risk of fractures Enhanced understanding of the regulation of this new phosphate-regulating hormone FGF-23 will advance the field of phosphate metabolism
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| K23DK073356 | NIH | None | httpsreporternihgovquickSearchK23DK073356 |